Cadila Pharmaceuticals

What Cadila Pharmaceuticals does

Cadila Pharmaceuticals Limited is a privately-held Indian pharmaceutical company founded in 1951 and headquartered in Ahmedabad, Gujarat. The company operates four core business verticals — APIs, Formulations, CDMO/CMO services, and CRO services — and is one of the largest privately-held pharma companies in India, employing 8,000+ people across operations in India, the USA, the UK, Russia, Kenya, Nigeria, Ethiopia, and Japan. Its portfolio spans 850+ finished dosage products across 45 therapeutic areas and 12 medical specialities, anchored by a series of world-first innovations including Risorine (anti-TB FDC with piperine bio-enhancer), Rabeloc IV (world's first IV rabeprazole), Polycap (five-in-one CV polypill), Calcirol AQ (world's first aqueous Vitamin D3 injection), Thrabis (world's first three-dose rabies vaccine), Sepsivac (heat-killed Mycobacterium w immunomodulator), Mycidac C (India's first indigenous DSC3-expressing NSCLC immunotherapy), and Cadiflu Tetra (India's first VLP-based quadrivalent influenza vaccine).

The company's technology base combines synthetic chemistry (180+ API Drug Master Files across USDMF, CEP, EDMF, JDMF, KDMF, TGA, TPD Canada, China IDL, TDMF, Russia, Cofepris), biologics manufacturing (mammalian, microbial, insect, and viral culture with single-use bioreactors), formulation science, and proprietary platforms including the Sf9/Baculovirus VLP vaccine platform, Tri-tab triple-layered tablet technology, and SMEDDS curcumin delivery. Backed by 300+ scientists and a 50,000 sq. ft. formulation R&D facility plus a 125+ scientist API R&D centre, Cadila holds 457 patents filed and 162 granted globally, with 1,700+ cumulative product registrations across regulated and semi-regulated markets.

Cadila generates revenue through B2B API supply to global pharmaceutical customers, branded generics and formulations sales through a large India field sales force targeting specialty physicians (25,000+ gynaecologists and 20,000+ orthopaedic specialists), vaccine and institutional supply to government immunisation programmes, CDMO/CRO contract services to third-party pharma clients, and consumer wellness products through its Chezgreen Division. Manufacturing is distributed across Dholka (formulations, biologics, CRO), Dahej (DCS-automated API facility launched November 2023), Ankleshwar (API), Jammu, Udaipur (lyophilised/critical care), and internationally in the USA and Ethiopia. Recent launches include Biscado (Bisoprolol, June 2025), Ciledge Trio (April 2026, world-first triple FDC antihypertensive using Tri-tab tech), and Subhadra Syrup (May 2026, herbal menstrual health via Chezgreen Division).

Name

Cadila Pharmaceuticals

Legal name

Cadila Pharmaceuticals Limited

Website

https://cadilapharma.com

Company type

Private

Founded year

1951

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Cadila Pharmaceuticals is a privately-held Indian pharmaceutical company founded in 1951, manufacturing 850+ formulations, APIs, biologics, vaccines, and herbal products across 45 therapies. It serves global markets via subsidiaries in the US, UK, Ethiopia, and other regions, with 8,000+ employees and a portfolio of world-first innovations.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)

Keywords

• Generic pharmaceutical formulations
• Active pharmaceutical ingredients
• Contract manufacturing services
• Clinical research services
• Vaccine development

Headquarters

HQ city

Ahmedabad

HQ country

India

HQ region

Asia

Offices15 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Branded generics and formulations sales: Sale of 850+ finished dosage products across 45 therapies and 12 specialities (tablets, capsules, injectables, ophthalmics) to wholesalers, distributors, retailers, and hospitals in India and international markets. Key brands include Polycap, Rabeloc, Calcirol, Thrabis, Sepsivac, Tambac, Symbiotik XL, Ferowall, Mycidac C, Ciledge Trio, Biscado, and others.
2. Active Pharmaceutical Ingredient (API) manufacturing and supply: B2B supply of high-quality APIs across gastroenterology, cardiovascular, CNS, antiemetic, anti-allergic, respiratory, diabetology, and pain management to global pharmaceutical customers. Backed by 180 API Drug Master Files (DMFs) across USDMF, CEP, EDMF, JDMF, KDMF, TGA, TPD Canada, China IDL, TDMF, Russia, and Cofepris dossiers. DCS-enabled Dahej facility supports efficient, sustainable production.
3. CDMO/CMO contract development and manufacturing services: Contract development and manufacturing solutions to speed the journey from molecule to market, providing affordable, safe, and life-changing therapies to clients. Stated successful CDMO track record in Botulinum Toxin and Antiplatelet–Anticoagulant domains for global partners.
4. CRO clinical research services: End-to-end clinical research services from BA/BE studies to Phase I–IV trials, conducted through CRO R&D-1 in Dholka, Ahmedabad. Supports third-party clinical development needs.
5. Biologics contract manufacturing and biosimilars supply: Biologics manufacturing leveraging Dholka DSIR-approved Biotechnology R&D and manufacturing facility. Commercial biologicals include Erythropoietin, Filgrastim, Streptokinase, and immunomodulatory agents. Provides CDMO partnerships in biologic domains.
6. Herbal/AYUSH consumer wellness products: Sales of Ayurvedic and herbal OTC wellness products under the Chezgreen Division, including Subhadra Syrup, Tummyease Capsule, KQMIN, Fleximuv-SG, Fleximuv-Cream, Happytizer, Umrela, Healtherbs, Hepasave, Folistrong, Cahaya, and N-T-Tus Lozenges.
7. Vaccines (VLP and recombinant): Sales of proprietary vaccines including Thrabis (world's first three-dose rabies vaccine), Cadiflu Tetra (VLP-based quadrivalent influenza vaccine), and the recombinant Rabies G protein nanoparticle-based vaccine. Vaccines are sold through government immunisation programmes and private channels.
8. Licensing and royalties (API DMFs and patents): Revenue generated through 180 API Drug Master Files, 457 patents filed and 162 patents granted globally, plus 1700+ product registrations. Licenses enable global partners to manufacture, distribute, or commercialise Cadila-developed products and processes under IP-protected terms.

Pricing tiers

Go-to-market motion1 record

Distribution channels9 records

Marketing channels8 records

Core offering

Cadila Pharmaceuticals develops, manufactures, and markets pharmaceutical products across four core business verticals: APIs, Formulations (850+ finished dosage products across 45 therapies and 12 medical specialities), CDMO & CMO services, and CRO clinical research services. The company also operates biologics/vaccine R&D and a herbal/Ayurvedic wellness portfolio (Chezgreen Division), with proprietary platforms including Tri-tab triple-layered tablet technology, Sf9/Baculovirus VLP vaccine platform, and DCS-automated API manufacturing.

Product overview

Cadila Pharmaceuticals operates a diversified pharmaceutical platform organised around four core business verticals — APIs, Formulations, CDMO & CMO services, and CRO services — supported by advanced biologics/vaccine R&D, herbal/Ayurvedic wellness, and a proprietary Tri-tab three-layer tablet technology platform. The Formulations business delivers 850+ finished dosage products across 45 therapy areas and 12 medical specialities, organised into therapeutic franchises such as Gastroenterology, Oncology, Cardiology, Diabetology (including Humstard premixed insulin, Jankey/Sitagliptin, Empadon/Empagliflozin, Dapagliflozin, Metformin), Neurology, Gynaecology (with the Haem-Up range), Orthopaedic, Dermatology & Cosmetology, Respiratory, Vaccines (ThRabis and Cadiflu Tetra), Anti-Infective (Tambac/Cefpodoxime, Symbiotik XL/Amoxiclav, Ferowall/Faropenem), Herbal/Ayurveda (Chezgreen Division brands such as KQMIN, Subhadra Syrup, Fleximuv, Tummyease, Umrela, Healtherbs, Hepasave, Folistrong, Cahaya, N-T-Tus Lozenges, Happytizer), Paediatric, and Critical Care (Sepsivac, Calcirol Blu). The API business spans 180+ API Drug Master Files with a DCS-equipped Dahej facility and a 125+ scientist chemistry R&D centre, while the CDMO/CRO arms provide end-to-end molecule-to-market and Phase I-IV clinical research services. The product portfolio is anchored by a series of world-first innovations — Risorine (anti-TB with piperine bio-enhancer), Rabeloc IV (world's first IV rabeprazole), Polycap (5-in-1 CV polypill), Calcirol AQ (world's first aqueous Vitamin D3 injection), ThRabis (world's first three-dose rabies vaccine), Envas IV (IV enalaprilat), Sepsivac (heat-killed Mycobacterium w immunomodulator), Mycidac C (India's first indigenous DSC3 lung cancer immunotherapy), and Cadiflu Tetra (India's first VLP-based quadrivalent influenza vaccine) — and recent commercial launches including Ciledge Trio (triple FDC antihypertensive using Tri-tab platform), Biscado (Bisoprolol), and the new Advanced Pharmaceutical Warehouse in Ahmedabad. Underpinning the enterprise are internal digital tools such as the Cadila LPE (Leading Performance Excellence) learning platform and the Mantra Leadership Program, all serving Cadila's mission of affordable, accessible global healthcare across more than 45 therapy areas.

Differentiator

Problem solved

Functional benefit

Brands

• Risorine: World-first fixed-dose combination of rifampicin, isoniazid, and piperine for tuberculosis treatment with reduced rifampicin dose.
• Rabeloc IV
• Polycap
• Calcirol AQ
• Thrabis (ThRabis)
• Envas IV
• Sepsivac
• Mycidac C
• Cadiflu Tetra
• Ciledge Trio
• Subhadra Syrup
• Biscado
• Immuvac
• Haem-Up
• Humstard

Products and services

• Ciledge Trio Triple fixed-dose antihypertensive combining Cilnidipine (CCB), Telmisartan (ARB), and Metoprolol (β1-blocker), built on Cadila's proprietary Tri-tab three-layer tablet platform for sustained BP control and cardiovascular protection. Targeted at hypertensive patients and cardiologists in India.
• Subhadra Syrup Herbal formulation launched under the Chezgreen Division to support menstrual health by helping regularise menstrual cycles and supporting management of amenorrhea, dysmenorrhea, and menorrhagia. Targeted at adult women in India seeking Ayurvedic wellness solutions.
• Risorine First-of-its-kind fixed-dose combination of rifampicin, isoniazid, and piperine (a natural bio-enhancer from black pepper) that allows a lower rifampicin dose (200 mg vs. 450 mg) with improved cure rates and safety in TB treatment. For TB patients in high-burden markets.
• Rabeloc IV World's first intravenous rabeprazole for fast, effective acid control in upper GI bleeding, stress ulcers, reflux, and perioperative care when oral therapy is not feasible. For hospitals and critical-care settings.
• Polycap Five-in-one fixed-dose combination of Simvastatin, Ramipril, Atenolol, Hydrochlorothiazide, and Aspirin in a single pill to improve adherence and reduce cardiovascular risk factors. For at-risk cardiovascular patients and cardiologists.
• Calcirol AQ World's first aqueous Vitamin D3 injection offering painless delivery, faster absorption, and quicker correction of deficiency compared with conventional oil-based Vitamin D3 injections. For paediatric and adult patients with Vitamin D deficiency.
• Thrabis (ThRabis) Three-dose intramuscular rabies vaccine administered within one week, designed to shorten the conventional five-dose regimen and improve compliance and protection in resource-limited settings. For post-exposure rabies prophylaxis in humans.
• Envas IV Rapid-onset intravenous Enalaprilat injection for acute management of hypertension and heart failure in critically ill patients where oral therapy is not an option. For hospitals and ICUs.
• Sepsivac

Quantifiable outcome

• Planted 2,000+ fruit-bearing and native plants in a single day across Shantivan-Dholka, Hirapur, Kadi, and other operational sites on World Environment Day 2026 (5 June)

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature15 records

Partnerships

Six partnerships are on record, tiered flagship, core and minor.

• Serum Institute of IndiaflagshipStrategic or Co-development PartnerCo-developed TB vaccines for Phase III clinical trial: Cadila's Immuvac and Serum Institute's VPM1002 were tested together in a large Phase III trial in India involving over 12,700 participants across 18 sites in six Indian states. VPM1002 demonstrated 50.4% efficacy against extra-pulmonary TB after three years and over 65% efficacy in people with latent TB infection. The trial was led and funded by the Indian Council of Medical Research (ICMR) and published in The BMJ.
• Indian Council of Medical Research (ICMR)flagshipStrategic or Co-development PartnerLed and funded the Phase III clinical trial of VPM1002 and Immuvac TB vaccines across 18 sites in six Indian states, involving over 12,700 participants. Trial results published in The BMJ. ICMR acts as the public-sector research and trial sponsor.
• Indrashil UniversitycoreStrategic or Co-development PartnerCadila Pharma has partnered with Indrashil University to launch the Campus to Corporate Initiative — a flagship program under the B-Pharma curriculum that prepares students for careers in pharmaceutical manufacturing operations. The course is co-developed by Cadila Pharma and Indrashil University, blends theoretical knowledge with practical experience, and offers career opportunities for outstanding performers.
• ICGEB, CSIR, NII, DST, and IMTECHcoreTechnology or IntegrationCollaborations with international and national research institutions including ICGEB (International Centre for Genetic Engineering and Biotechnology), CSIR (Council of Scientific and Industrial Research), NII (National Institute of Immunology), DST (Department of Science and Technology), and IMTECH (Institute of Microbial Technology) for biologics development and translational research.
• EQL Pharma ABminorOthersRajiv I. Modi (Chairman & Managing Director of Cadila Pharmaceuticals Ltd.) represents Cadila as a member of EQL Pharma's Nomination Committee for the 2026 Annual General Meeting to be held in Lund on 20 August 2026. The committee prepares proposals for board elections, auditor appointment, and related matters ahead of the AGM. Other members are Christer Fåhraeus (Fårö Capital AB) and Sten Irwe.
• Ahmedabad & Vadodara pharmaceutical hub ecosystemcoreOthersCadila Pharmaceuticals is identified as one of the key companies in India's Ahmedabad & Vadodara pharmaceutical manufacturing hub, contributing to India's role in global pharma supply chains and innovation through its Dholka, Dahej, Ankleshwar, and Jammu facilities.

Scale indicators16 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Torrent Pharmaceuticals: Large privately-influenced Indian pharma with diversified branded generics, APIs, and CDMO across cardiovascular, diabetology, gastroenterology, and CNS — directly comparable to Cadila's therapy mix and India-focused field sales model.
• Alembic Pharmaceuticals: Indian pharma with parallel API manufacturing (USDMF/CEP filings), branded generics across cardiology/anti-infective, and US generics business — closely comparable to Cadila's API-plus-formulations dual-engine model.
• Ipca Laboratories: Indian API-led pharma with strong DMF pipeline, branded generics in anti-malarial/anti-infective, and emerging international generics business — directly comparable in API scale and emerging markets presence.
• Serum Institute of India: World's largest vaccine manufacturer by doses; co-developed TB vaccines with Cadila (VPM1002 + Immuvac Phase III trial) and operates VLP/recombinant vaccine platforms directly comparable to Cadila's Sf9/BV platform.
• Biocon: India's leading biosimilars and biologics company with Mammalian/microbial platforms and global CDMO partnerships — closely comparable to Cadila's biologics platform (Erythropoietin, Filgrastim, Streptokinase) and CDMO ambitions.

Broad incumbents

• Cipla: India's largest privately-influenced pharma with respiratory, cardiology, and anti-infective franchises plus strong Africa presence — comparable in India+Africa emerging markets distribution and Indian field-sales-led model.
• Dr. Reddy's Laboratories: Large listed Indian pharma with comparable branded generics, biosimilars, APIs, and a substantial US generics business — overlapping therapy areas and global distribution strategy.
• Lupin: One of India's largest listed pharma companies with branded generics, complex APIs, biosimilars, and global CDMO; significantly larger scale than Cadila but directly comparable therapy mix and emerging markets footprint.
• Sun Pharmaceutical Industries: India's largest pharma company with chronic-disease branded generics, complex APIs, and global specialty presence; directly competes with Cadila in cardiology, diabetology, and gastroenterology in India and emerging markets.
• Aurobindo Pharma: Large listed Indian pharma with comparable API DMF scale (USDMF/CEP), US generics focus, and injectable manufacturing — competing with Cadila in B2B API and global generics markets.

Market position

Strengths1 record

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Cadila_Pharma
• YouTubeyoutube.com/channel/UCtE71y-ursyxkcqdO-elnWQ
• Facebookfacebook.com/officialcadilapharma
• LinkedInlinkedin.com/company/cadila-pharmaceuticals
• Instagraminstagram.com/cadilapharmaceuticals

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cadila Pharmaceuticals